Birds and humans have different types of receptors in their respiratory tract that flu viruses attach to, like a lock ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Key targets of the programme are elderly people and children. This programme is a part of Sanofi's commitment to improving ...

Sanofi is end­ing a Phase 2 clin­i­cal tri­al that’s test­ing a drug from De­nali for mul­ti­ple scle­ro­sis, putting a stop to the de­vel­op­ment plan. … ...

The FDA has approved updated labeling for Flublok (influenza vaccine) to include new safety data involving pregnant individuals.

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

High-dose flu vaccinations resulted in a 23% reduction in hospitalizations among people aged 65 years or older, according to ...

France’s Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have agreed to combine their expertise to further accelerate the ...